Liquid Biopsy–Detected EGFR S645C Driving a Striking and Durable Complete Response to Afatinib: A Case Report

Read full text Summarise with VIRAT
Authors: Letizia Padula, Alice Ilari, Davide Seminati, Diego Luigi Cortinovis, Luca Sala
Cited by: 0
References: 22

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Uncommon mutations in the EGFR gene currently represent both a diagnostic and therapeutic challenge in non-small cell lung cancer (NSCLC).This is a rarity in oncology, characterized by a different response to tyrosine kinase inhibitors (TKIs) due to the heterogeneity that characterizes each individual mutation, making it even more complex to understand the correct treatment to administer to this class of patients.This case report presents the case of a woman with recurrent lung adenocarcinoma in whom the EGFR S645C (exon 17) mutation detected in liquid biopsy after disease progression on anti-PD-L1 immunotherapy.The patient was therefore treated with Afatinib, a second-generation TKI, with a partial and then complete clinical and radiological response for more than nine months.After initial toxicity with G3 diarrhea related to treatment at the maximum dose, the dose was reduced with excellent tolerance to therapy (from 40 to 20mg/day).The EGFR S645C mutation was identified only through repeat molecular testing using liquid biopsy, as no indication for tissue re-biopsy was present.This finding enabled targeted treatment, improved patient survival, and supports the efficacy of afatinib in rare EGFR mutations.

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Cancer Genomics and Diagnostics Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
Journal of Oncology Research and Therapy
Volume
11
Issue
1
Publication date
13 March 2026
Language
EN